Palantir rose after earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted on ...

Anthropic has officially released its new flagship AI, Claude Opus 4.1, an incremental upgrade designed to boost coding and ...

Anthropic says Claude Opus 4.1 improves software engineering accuracy to 74.5%. That compares to 62.3% with Claude Sonnet 3.7 and 72.5% with Claude Opus 4. More specifically, the updated model is ...

Anthropic has released Claude Opus 4.1, a new version of its flagship AI model, with improvements in coding, reasoning, and ...

Anthropic, on Tuesday, announced a new version of its AI model, the Claude Opus 4.1, just as rival OpenAI is getting close to ...

A Massachusetts biotech working on a class of medicines called circular RNA therapeutics beat out companies from around the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase ...

Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178 % ...

Palantir Technologies reported after the market closed yesterday and had another blowout quarter. Berkshire Hathaway was a ...

There’s a man named Mark who can control an iPad with his thoughts. Others will soon join him, thanks to a new partnership between Apple and Synchron. It’s the latest step forward for a field that a ...

Newton Research announced its $9 million Series A raise on Tuesday. The funds will increase hiring as demand for Newton's ...